Alzheimer’s Disease/Dementia News

Marriage was associated with a lower risk for dementia and mild cognitive impairment in later life, researchers reported in the Journal of Aging and Health.

Reduced kidney function was associated with increased levels of dementia-related blood biomarkers, but not an increased risk for Alzheimer’s disease or dementia, researchers reported in JAMA Network Open.

The FDA issued a complete response letter on the accelerated approval of donanemab for treatment of early symptomatic Alzheimer’s disease, citing the limited number of patients with longer drug exposure data.

Hormone therapy may promote better memory and cognitive function and larger brain volumes among women carrying APOE4, a genetic risk factor for Alzheimer’s disease.

Cardiometabolic multimorbidity and midlife onset of cardiometabolic disease are significantly associated with an increased risk for dementia, and genetic background may underlie this association, researchers reported.

Cerveau Technologies Inc. announced a partnership with Othair Prothena Limited, which will allow Prothena to use Cerveau’s investigational imaging agent in positron emission tomography scans to assess neurofibrillary tangles in the brain.

Moderate to severe hearing loss was associated with a higher prevalence of dementia among older adults, a research letter in JAMA reported.

The manufacturer of Leqembi announced it has submitted a supplemental Biologics License Application to the FDA to support the conversion of its recent accelerated approval to a traditional approval.

The FDA has determined that the supplementary new drug application for brexpiprazole, a drug to treat agitation associated with Alzheimer’s dementia, is sufficiently complete to permit a substantive review, according to the manufacturers.

Quanterix Corp. announced the validation of a laboratory developed test to quantitatively measure neurofilament light chain in serum as an aid in the evaluation of those who may have neurodegenerative conditions.